Literature DB >> 9168438

c-kit Point mutation in patients with myeloproliferative disorders.

A Kimura1, Y Nakata, O Katoh, H Hyodo.   

Abstract

Myeloproliferative disorders (MPD) constitute a group of hematopoietic neoplasms at the myeloid stem cell level. Myeloid stem cells and/or progenitor cells from MPD have been considered sensitive to hematopoietic growth factors, including erythropoietin, thrombopoietin and stem cell factor (SCF). SCF is a ligand for c-kit receptor with tyrosine kinase. We analysed the gene alteration of the c-kit extracellular domain in MPD patients by PCR-SSCP and subsequent nucleotide sequencing. The point mutation in the N-terminal part of the domain, codon 52 (Asp-->Asn), was found in two patients with primary myelofibrosis and one with chronic myelogenous leukemia. We review the literature regarding the role of SCF/c-kit system in the oncogenesis of leukemia and MPD, and then discuss the significance of our finding in the context of growth advantage of the mutated clones over the normal clones.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168438     DOI: 10.3109/10428199709114167

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

2.  Beginning of personalized medicine in Panama: Molecular and pathological characteristics of gastrointestinal stromal tumors from archival paraffin-embedded tissue.

Authors:  Yaxelis Mendoza; Carlos Singh; Juan Castillo Mewa; Evelise Fonseca; Rebecca Smith; Juan M Pascale
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

3.  The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.

Authors:  C Alhan; T M Westers; E M P Cremers; C Cali; B I Witte; G J Ossenkoppele; A A van de Loosdrecht
Journal:  Leukemia       Date:  2015-10-27       Impact factor: 11.528

Review 4.  Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.

Authors:  Maryam Abbaspour Babaei; Behnam Kamalidehghan; Mohammad Saleem; Hasniza Zaman Huri; Fatemeh Ahmadipour
Journal:  Drug Des Devel Ther       Date:  2016-08-01       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.